Clinical Trial Update: An Extension Study of Ataluren (PTC124) in Participants With Nonsense Mutation Dystrophinopathy [Phase 3]

View source ↗

Summary

Phase 3 extension study for ataluren (PTC124) in nonsense mutation dystrophinopathy was terminated; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• ataluren (ataluren)

Snippet

Sponsor: PTC Therapeutics | Conditions: Muscular Dystrophy, Duchenne, Muscular Dystrophies | Phase 3 | Status: TERMINATED | Results posted: 2020-08-11